Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927272 | 0.89 | MAPT (0.47) | HPGDMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL926837 | 0.87 | THRB (0.41) | HPGDMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL927449 | 0.83 | CNR2 (0.44) | HPGDMAPTALDH1A1KDM4ETP53 | |
| SCHEMBL926847 | 0.83 | CNR2 (0.46) | HPGDMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL928719 | 0.77 | CNR2 (0.46) | HPGDMAPTKDM4ETDP1HSD17B10 | |
| SCHEMBL4794563 | 0.76 | CNR2 (0.45) | HPGDMAPTALDH1A1LMNAL3MBTL1 | |
| SCHEMBL2162606 | 0.75 | ANO1 (0.43) | ANO1HPGDMAPTALDH1A1KDM4E | |
| SCHEMBL926977 | 0.74 | KMT2A (0.48) | HPGDMAPTALDH1A1KDM4ETDP1 | |
| SCHEMBL18300332 | 0.74 | KMT2A (0.58) | MAPTALDH1A1KDM4ETDP1LMNA | |
| SCHEMBL2163850 | 0.73 | ANO1 (0.44) | ANO1HPGDMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868038-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-01-11 | — | — | US | claimed |
| US-20080058307-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | claimed |
| US-8598224-B2 | Method for treating cannabinoid receptor related diseases with cannabinoid receptor ligands | ABBVIE INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20110086838-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7868038-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-01-11 | — | — | US | disclosed |
| US-20080058307-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058307-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPSR1 | ANO1 3840/4885HPGD 3098/4885MAPT 2116/4885 |
| US-20110086838-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPSR1 | ANO1 3840/4885HPGD 3098/4885MAPT 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.